Alexion Exercises its Option to License Dicerna’s Two Additional GalXC RNAi Programs

 Alexion Exercises its Option to License Dicerna’s Two Additional GalXC RNAi Programs

Alexion Exercises its Option to License Dicerna’s Two Additional GalXC RNAi Programs

Shots:

  • Alexion to pay $20M as an option exercise fee in exchange for exclusive rights to two additional targets within the complement pathway for the discovery and development of GalXC RNAi molecules
  • In Oct’2018, the companies collaborated to develop GalXC RNAi (SC) targeting four complement pathway therapies for the treatment of complement-mediated diseases. Under the collaboration, Alexion got exclusive WW rights for two candidates with an option to license for another two GalXC RNAi molecule while Dicerna is eligible to receive milestones and royalties on sales
  • Exercising an option marks the expansion of their existing research collaboration and license agreement to now encompass four targets within the complement pathway

Click here ­to­ read full press release/ article | Ref: Alexion | Image: The street

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post